Cyclacel Limited

Shanghai Genomics, Inc.

Cyclacel Limted

Shudong Wang

Peter Martin Fischer

Gavin Wood

Christopher Meades

Campbell McInnes

Nikolai Zhelev

Janice O'Boyle

Andrew Osnowski

Ying Luo

Nicholas James Westwood

Fang Rui Shu

Daniella I Zheleva

Kenneth Duncan

Janice McLachlan

Mark Thomas

David Blake

Darren Gibson

Alex Perry

Neil McIntyre

Kenneth W Duncan

Janice C Mclachlan

Campbell Mcinnes

Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.

Kinase inhibitors and their use as pharmaceutical agents

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein Rand Rare each independently H, C(OR) or a hydrocarbyl group optionally substituted by one or more Rgroups; Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.

Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders. 

Pyrimidine compounds

A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; 'a' is a single bond; or 'a' is a double bond and one of Rand R, and one of Rand Rare absent; Ris H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO-alkyl, CORand an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from Rand R; Ris H, R, or an alkyl group optionally substituted with one or more Rgroups; R, R, R, and Rare each independently selected from H, R, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more Rgroups; or Rand R, and/or Rand Rtogether represent &#x2550;O; Ris H, R, NH(CH)R, CO(CH)R, NHCO(CH)R, O(CH)R, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from Rand R; Ris OR, NRR, halogen, CF, NO, COR, CN, COOR, CONRR, SORor SONRR; Ris a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more Rgroups; R, R, Rand Rare each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds

N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds

Inhibitors of cyclin dependent kinases as anti-cancer agent

The invention relates to modified and truncated forms of the membrane transport vector penetratin. Such truncated forms include 7-mer peptides that may in themselves include further variation.

Transport vectors

The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.

Carrier based drug delivery system

Anti-cancer compounds

Growing community of inventors

Angus, United Kingdom

Shudong Wang